Literature DB >> 11852052

Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.

Harry J Witchel1, Vijay K Pabbathi, Giovanna Hofmann, Ashok A Paul, Jules C Hancox.   

Abstract

Using whole-cell patch clamp recording of heterologous HERG-mediated currents in transfected mammalian cells, we observed that the selective serotonin re-uptake inhibitor citalopram blocks HERG with an IC(50) of 3.97 microM. This is slightly less potent than fluoxetine in our system (IC(50) of 1.50 microM). In isolated guinea pig ventricular cardiomyocytes citalopram inhibited L-type calcium current (I(Ca,L)). The voltage dependence of I(Ca,L) inactivation in the presence of 100 microM citalopram was shifted significantly leftward. As a result, the I(Ca,L) 'window' in citalopram was found to be (a) smaller and (b) leftward-shifted compared to control. The effects of citalopram on both calcium current amplitude and the I(Ca,L) 'window' may help to explain citalopram's good cardiac safety profile, given its propensity to block HERG at excessive dosages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11852052     DOI: 10.1016/s0014-5793(01)03320-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

1.  Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.

Authors:  Eberhard P Scholz; Edgar Zitron; Claudia Kiesecker; Sonja Lueck; Sven Kathöfer; Dierk Thomas; Slawomir Weretka; Simon Peth; Volker A W Kreye; Wolfgang Schoels; Hugo A Katus; Johann Kiehn; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-14       Impact factor: 3.000

2.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Authors:  Marion Aubert; Rolf Osterwalder; Björn Wagner; Isabelle Parrilla; Icilio Cavero; Lucette Doessegger; Eric A Ertel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.

Authors:  Nikunjkumar Patel; Barbara Wiśniowska; Masoud Jamei; Sebastian Polak
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

5.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

6.  Escitalopram block of hERG potassium channels.

Authors:  Yun Ju Chae; Ji Hyun Jeon; Hong Joon Lee; In-Beom Kim; Jin-Sung Choi; Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-18       Impact factor: 3.000

7.  Citalopram and escitalopram: adverse cardiac outcomes in medically ill inpatients.

Authors:  Dominique Elie; Saeid Noohi; André Do; Artin Mahdanian; Ching Yu; Marilyn Segal; Karl J Looper; Soham Rej
Journal:  Ther Adv Drug Saf       Date:  2016-07-19

8.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

9.  Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.

Authors:  Edgar Zitron; Claudia Kiesecker; Eberhard Scholz; Sonja Lück; Ramona Bloehs; Sven Kathöfer; Dierk Thomas; Johann Kiehn; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-29       Impact factor: 3.000

Review 10.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.